Literature DB >> 27754929

NOX1/NADPH Oxidase Expressed in Colonic Macrophages Contributes to the Pathogenesis of Colonic Inflammation in Trinitrobenzene Sulfonic Acid-Induced Murine Colitis.

Haruka Yokota1, Ayaka Tsuzuki1, Yuki Shimada1, Azusa Imai1, Daichi Utsumi1, Takuya Tsukahara1, Misaki Matsumoto1, Kikuko Amagase1, Kazumi Iwata1, Akio Nakamura1, Chihiro Yabe-Nishimura1, Shinichi Kato2.   

Abstract

NOX1/NADPH oxidase, a nonphagocytic isoform of reactive oxygen species-producing enzymes, is highly expressed in the colon, but the physiologic and pathophysiologic roles of this isoform are not fully understood. The present study investigated the role of NOX1 in the development of colonic inflammation in a trinitrobenzene sulfonic acid (TNBS)-induced murine colitis model. Intrarectal injection of TNBS caused severe colitis accompanied by body weight loss, diarrhea, and increased myeloperoxidase (MPO) activity in wild-type (WT) mice. In contrast, the severity of colitis was significantly attenuated in NOX1-deficient (NOX1KO) mice (the inhibitions of macroscopic damage score, body weight loss, diarrhea score, and MPO activity were 73.1%, 36.8%, 83.3%, and 98.4%, respectively). TNBS-induced upregulation of inflammatory cytokines (tumor necrosis factor (TNF)-α and interleukin (IL)-1β), chemokines (CXCL1 and CXLC2), and inducible nitric oxide synthase (iNOS) was also significantly less in NOX1KO than in WT mice (the inhibitions were 100.8%, 89.0%, 63.5%, 96.7%, and 97.1%, respectively). Expression of NOX1 mRNA was detected not only in the lamina propria but also in peritoneal macrophages isolated from WT mice. Increased expression of TNF-α, IL-1β, and iNOS in peritoneal macrophages exposed to lipopolysaccharide was significantly attenuated in macrophages isolated from NOX1KO mice (68.1%, 67.0%, and 79.3% inhibition, respectively). These findings suggest that NOX1/NADPH oxidase plays an important role in the pathogenesis of TNBS-induced colonic inflammation via upregulation of inflammatory cytokines, chemokines, and iNOS. NOX1 in colonic macrophages may become a potential target in pharmacologic intervention for inflammatory bowel disease.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27754929     DOI: 10.1124/jpet.116.235580

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Alisol B 23-Acetate Ameliorates Lipopolysaccharide-Induced Intestinal Barrier Dysfunction by Inhibiting TLR4-NOX1/ROS Signaling Pathway in Caco-2 Cells.

Authors:  Fan Xia; Yuxin Li; Lijun Deng; Ruxia Ren; Bingchen Ge; Ziqiong Liao; Shijian Xiang; Benjie Zhou
Journal:  Front Pharmacol       Date:  2022-06-14       Impact factor: 5.988

2.  NAD(P)H Oxidase Activity in the Small Intestine Is Predominantly Found in Enterocytes, Not Professional Phagocytes.

Authors:  Randall L Lindquist; Jannike Bayat-Sarmadi; Ruth Leben; Raluca Niesner; Anja E Hauser
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

3.  The Nox1/Nox4 inhibitor attenuates acute lung injury induced by ischemia-reperfusion in mice.

Authors:  Yu Cui; Yu Wang; Gen Li; Wan Ma; Xiao-Shuang Zhou; Jia Wang; Bin Liu
Journal:  PLoS One       Date:  2018-12-20       Impact factor: 3.240

4.  Protective Effect of Iridoid Glycosides of the Leaves of Syringa oblata Lindl. on Dextran Sulfate Sodium-Induced Ulcerative Colitis by Inhibition of the TLR2/4/MyD88/NF-κB Signaling Pathway.

Authors:  Yifang Zhang; Dandan Han; Shen Yu; Chiying An; Xin Liu; Haijing Zhong; Yuan Xu; Lianzhou Jiang; Zhongjiang Wang
Journal:  Biomed Res Int       Date:  2020-03-30       Impact factor: 3.411

5.  Interleukin-4 Receptor α Subunit Deficiency Alleviates Murine Intestinal Inflammation In Vivo Through the Enhancement of Intestinal Mucosal Barrier Function.

Authors:  Ai Hertati; Shusaku Hayashi; Yudai Ogawa; Takeshi Yamamoto; Makoto Kadowaki
Journal:  Front Pharmacol       Date:  2020-10-28       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.